NL-OMON25483招募中不适用
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers duringthe perioperative period: to withdraw or to continue? A multicenter randomized controlled trial.
niversity Medical Center Utrecht, The Netherlands0 个研究点目标入组 3,200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 3,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •-Chronic ACEI or ARB use for the treatment of hypertension. Patients who use a com-bination pill with a diuretic are eligible as well;
- •-Scheduled for elective intermediate to high risk noncardiac surgery, defined according to the European Society of Cardiology / European Society of Anesthesiology guidelines on noncardiac surgery;
- •-Expected postoperative length of stay of at least two days.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •-Severe chronic kidney disease, defined as GFR<30 ml/min/1.73 m2;
- •-ACEI/ARB use for the treatment of chronic systolic heart failure, defined as left ven-tricular ejection fraction =40%;
- •-ACEI/ARB use within one year after ST-elevated myocardial infarction, according to the fourth universal definition of myocardial infarction;
- •-Transplant surgery;
- •-ACEI/ARB use in a combination pill together with a drug other than a diuretic, including calcium channel blockers, beta-blockers and neprilysin inhibitors;
- •-Use of drugs acting on the renin-angiotensin-aldosterone system other than ACEI/ARB, e.g. aliskiren.
研究者
相似试验
已完成
不适用
Angiotensin Converting Enzyme (ACE) inhibition for the preservation of renal function and patient survival in kidney transplantatioChronic kidney disease in renal transplant patientsUrological and Genital DiseasesChronic kidney diseaseISRCTN78129473Ottawa Hospital Research Institute (OHRI) (Canada) - formerly Ottawa Health Research Institute528
进行中（未招募）
1 期
Angiotensin Converting Enzyme Inhibitor (ACE) Induced AngioedemaBERINERTRandomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced AngioedemaAngiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and neck region. These can lead to severe dyspnoea and the need for intubation and are thought to be bradykinin mediated. Up until now there is no study-evaluated conservative therapeutic concept for the treatment of these patients.MedDRA version: 18.1Level: HLTClassification code 10002425Term: AngioedemasSystem Organ Class: 100000004870EUCTR2012-001670-28-DEMedizinische Fakultät der Technischen Universität München52
进行中（未招募）
不适用
ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuriaThe primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documentedMedDRA version: 9.1Level: SOCClassification code 10038359Term: Renal and urinary disordersEUCTR2005-003885-40-ITAZIENDA OSPEDALIERA PROVINCIALE DI LECCO
已完成
3 期
The Effect of Angiotensin Convetring Enzyme Inhibitor on the Quality of Life of Non Hospitalized Patients With Cancer Cachexia in Shiraz University ClinicsGastric cancer.Malignant neoplasm of stomachIRCT2014050511375N3Shiraz University of Midical Sciences40
已完成
不适用
Effect of Angiotensin Converting Enzyme Inhibition (ACEI) on C-Reactive Protein (CRP) Levels: The Ramipril CRP Randomized Evaluation (4R Trial)Healthy volunteers with elevated levels of C-Reactive proteinCirculatory SystemISRCTN31129526Sanofi-Aventis (Canada)400